About US
Contact us
-
Novartis LEE011 receives FDA Priority Review for first-line treatment of HR+ / HER2- advanced breast cancerThe US Food and Drug Administration (FDA) has accepted Novartis' New Drug Application (NDA) for filing and granted Priority Review for LEE011 (ribociclib) as first-line treatment of postmenopausal wom2016/11/1
-
Drug flippers exploit pharma's price-hike climate for fast profitHefty drug price increases have been an outrage-provoking subject for politicians, the public and pharmacy benefits managers all year long. But another group besides drugmakers hasbeen benefiting from2016/10/31
-
Hot immuno-oncology combos can trigger rare but fatal heart damage: NEJMTwo prominent doctors have flagged a serious and unexpected side effect linked to the immuno-oncology drugs taking cancer treatment by storm: heart damage that can be fatal. In aNew England Journal o2016/10/31
-
Eisai wins NICE backing for older Halaven but still isn't happy about LenvimaAfter weighing new data and a discount, England’s drug-cost watchdogsbackedEisai’s Halavento treat advanced breast cancer, making it the first drugto win a green lightin breast cancer in nearly a deca2016/10/28
-
Why is Valeant's 'blockbuster' libido drug Addyi a dud? Shoddy marketing, investor lawsuit claimsWhen Valeant bought Sprout Pharmaceuticals and its controversial female libido drug Addyi, it agreed to a marketing blitz that would bring royalties to Sprout's former shareholders. Valeant bungled th2016/10/28
-
Allergan's handling of Q3 'black eye' dings confidence in management: AnalystAllergan’s third-quarter numbersweren’t good. But neither was the way the company talked about them, one analyst says, and that’s even more worrisome. On Wednesday, Allergan disclosed that revenue ha2016/10/27
-
More Valeant up for bid? Beseiged pharma weighs $2.5B sale of eye-surgery bizAnother day, another Valeant asset sale rumor. Less than 24 hours after word got out that Valeant and Takeda were in Salix deal talks, the embattled drugmaker is said to be exploring a sale of its eye2016/10/27
-
ASHLAND INDUSTRIES NEDERLAND’S ZWIJNDRECHT SITE RECEIVESNEWS RELEASEASHLAND INDUSTRIES NEDERLAND’S ZWIJNDRECHT SITE RECEIVESEXCiPACT GMP CERTIFICATION AS PHARMACEUTICAL EXCIPIENTSUPPLIERSBrussels, 25 October 2016EXCiPACT asbl is delighted to announce that2016/10/26
-
J&J pushes to move talcum powder cancer lawsuits to NJ, where it's won twoAt least 18 federal lawsuits claiming Johnson & Johnson’s ($JNJ) talc-based powders caused ovarian cancer could be consolidated for pretrial work, and J&J wants that litigation in New Jersey,2016/10/26
-
Colombia makes good on Gleevec pricing threat with plans for 45% cutA tense, months-long pricing standoff with Novartis escalated late last week as Colombia decided to take the radical step it had been threatening: The country plans to cut the price of leukemia med Gl2016/10/25